GILEAD SCIENCES, INC. Operating Income Loss

• GILEAD SCIENCES, INC. showed an increase of +503.0% in Operating Income Loss from 2024 to 2025.
• This data is from GILEAD SCIENCES, INC.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
• XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 18 years of available data (2008 to 2025), GILEAD SCIENCES, INC.'s Operating Income Loss has grown by 274.2%.
• Historical annual values: Fiscal year 2025: $10.02 billion | Fiscal year 2024: $1.66 billion | Fiscal year 2023: $7.61 billion | Fiscal year 2022: $7.33 billion | Fiscal year 2021: $9.92 billion | Fiscal year 2020: $4.07 billion | Fiscal year 2019: $4.29 billion | Fiscal year 2018: $8.20 billion | Fiscal year 2017: $14.12 billion | Fiscal year 2016: $17.63 billion | Fiscal year 2015: $22.19 billion | Fiscal year 2014: $15.27 billion | Fiscal year 2013: $4.52 billion | Fiscal year 2012: $4.01 billion | Fiscal year 2011: $3.79 billion | Fiscal year 2010: $3.96 billion | Fiscal year 2009: $3.53 billion | Fiscal year 2008: $2.68 billion.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026